+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
DNA Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
DNA Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

DNA Vaccine Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083121
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The DNA Vaccine Market grew from USD 302.54 million in 2024 to USD 344.45 million in 2025. It is expected to continue growing at a CAGR of 13.74%, reaching USD 655.13 million by 2030.

The promise of DNA vaccines has emerged as a game changer in preventive and therapeutic immunization, leveraging the body’s own cellular machinery to generate robust immune responses against a diverse array of pathogens and disease targets. Building on decades of research into plasmid design, delivery vectors, and antigen engineering, DNA platforms now stand at the cusp of widespread adoption in both human and animal health. Beyond the rapid development timelines and scalable manufacturing advantages, these vaccines offer improved stability, lower cold-chain requirements, and the flexibility to target emerging threats with genetic precision. As regulatory frameworks evolve to incorporate novel modalities, stakeholders are revisiting traditional paradigms of vaccine development. Today’s landscape equals a convergence of scientific innovation, digital tools, and collaborative partnerships, reinforcing DNA vaccines as a cornerstone of next-generation disease prevention. This introduction sets the stage for a deeper analysis of the transformative shifts, tariff impacts, segmentation insights, regional dynamics, and corporate strategies that shape the DNA vaccine ecosystem.

Transformative Shifts in the DNA Vaccine Landscape

An unprecedented convergence of molecular biology breakthroughs and delivery innovations has redefined the vaccine landscape. First, the integration of synthetic biology and advanced plasmid design has accelerated antigen optimization, yielding candidates with higher immunogenicity and broader coverage. Second, novel delivery methods such as electroporation and nanoparticle carriers have enhanced cellular uptake, improving both safety and efficacy profiles. Third, strategic alliances between biotech startups and established pharmaceutical firms have catalyzed resource sharing, risk mitigation, and agile development pipelines. In parallel, digital health platforms are streamlining clinical trial recruitment and real-time data analytics, expediting go/no-go decisions. Together, these shifts empower manufacturers to respond rapidly to emerging infectious threats, personalize oncology vaccines, and expand prophylactic applications in veterinary medicine. Such transformative dynamics are reshaping R&D priorities, regulatory expectations, and commercial strategies, heralding a new era of precision immunization.

Cumulative Impact of United States Tariffs 2025

New tariff measures slated for implementation in 2025 will reverberate across the DNA vaccine supply chain, potentially raising costs for key raw materials and delivery devices. Higher duties on plasmid backbone components and lipid-based carriers may elevate production expenses, prompting manufacturers to reassess sourcing strategies and invest in domestic supply capabilities. At the same time, increased import levies on specialized instrumentation used for electroporation and bioreactor fermentation could disrupt existing logistics networks. In response, industry players are negotiating long-term agreements with U.S. suppliers to buffer against price volatility and exploring tariff mitigation tools such as foreign-trade zones and bonded warehouses. While these cumulative impacts introduce short-term headwinds, they also incentivize onshore capacity expansion, fostering local innovation hubs and strengthening supply chain resilience.

Key Segmentation Insights

Analysis by end-user application reveals that human vaccination continues to attract the lion’s share of R&D investment, driven by oncology and emerging infectious disease programs, while companion animal vaccination exhibits rapid innovation in prophylactic DNA constructs targeting zoonotic spillover prevention. Livestock immunization benefits from streamlined regulatory pathways for herd management, encouraging vaccine developers to pursue multivalent formulations. Within product type, prophylactic DNA candidates dominate early-stage pipelines, yet therapeutic DNA vaccines targeting cancer and chronic viral infections show accelerated progress in clinical trials, buoyed by advances in immune checkpoint combination strategies. Evaluation of technology platforms underscores plasmid DNA as the workhorse of the field, complemented by emerging mRNA and viral vector hybrids that enhance antigen presentation. Delivery method insights point to intramuscular injection with electroporation as the frontline approach, while intradermal and mucosal routes garner interest for mucosal immunity and dose-sparing potential. When disease indication is considered, infectious diseases maintain primary focus, particularly respiratory and gastrointestinal infections, whereas oncology DNA vaccines expand into personalized neoantigen targets. Injectable administration remains predominant, although nasal and oral formulations are under investigation for needle-free delivery. Segmentation by target population highlights adult and pediatric cohorts as primary beneficiaries, with geriatric inclusion growing to address immunosenescence. Research and development phases span the full spectrum from preclinical discovery to Phase III validation, showcasing a robust pipeline of next-generation constructs. Approval processes reflect a dual-track scenario, where emergency use authorization expedited certain programs during recent outbreaks, while full approval pathways solidify long-term market access. Business models range from in-house manufacturing by established biopharmas to outsourced production by specialized contract development organizations. Finally, sales channels balance direct sales agreements with leading healthcare institutions and distribution through retail and online pharmacies, ensuring comprehensive market reach and accessibility.

Key Regional Insights

In the Americas, robust funding for biotech R&D and supportive regulatory agencies have propelled DNA vaccine development across both clinical and veterinary applications. Public-private partnerships, especially in the United States and Canada, bolster early-stage discovery and expedite emergency use authorizations when rapid responses are required. In Europe, Middle East & Africa, harmonized frameworks like the European Medicines Agency’s guidelines and collaborative initiatives among Gulf states foster multicountry clinical trials and shared manufacturing hubs. Diverse pathogen landscapes-from respiratory pandemics in Europe to vector-borne threats in Africa-drive region-specific programs. Asia-Pacific boasts a dynamic ecosystem with technology giants in China, Japan, and South Korea investing heavily in plasmid manufacturing capacity. Government-led biotech parks and favorable intellectual property regimes support rapid scale-up, while Southeast Asian nations focus on tropical disease targets. Across all regions, regulatory agility, infrastructure investments, and strategic alliances dictate regional leadership in the DNA vaccine arena.

Key Company Insights

Major pharmaceutical and biotech companies are actively shaping this field through diverse approaches. Large-cap innovators such as Amgen Inc., AstraZeneca plc, Johnson & Johnson, Merck & Co., Inc., and Novartis AG leverage in-house manufacturing capabilities and extensive clinical networks to advance late-stage DNA vaccine candidates in oncology and viral pathogens. Specialized firms like Inovio Pharmaceuticals, Inc., Immunomic Therapeutics, Inc., and Vaccibody AS focus on proprietary plasmid platforms and pioneering delivery technologies to carve niche leadership in personalized and mucosal vaccines. Meanwhile, contract development organizations and platform providers-including Bioject Medical Technologies Inc., ExcellGene SA, TechnoVax Inc., and Vical Incorporated-support scalable manufacturing and formulation expertise. GeneOne Life Science, Inc., GeoVax Labs, Inc., and OncoSec Medical Incorporated bring innovative viral vector hybrids and electroporation solutions to augment immunogenicity. Emerging biotechs such as Emergent BioSolutions, Profectus BioSciences, Inc., and Vaxess Technologies Inc. are forging partnerships to enhance global access and drive pipeline diversification. Collectively, these players create a competitive yet collaborative ecosystem, fueling rapid iteration from bench to bedside.

Actionable Recommendations for Industry Leaders

Industry leaders can capitalize on several strategic imperatives. First, strengthening in-region manufacturing footprint through joint ventures will reduce tariff exposure and improve supply chain agility. Second, investing in advanced delivery research-such as mucosal and intradermal platforms-will differentiate product portfolios while addressing unmet immunological niches. Third, pursuing cross-sector collaborations that integrate artificial intelligence for antigen design and trial optimization will accelerate timelines and enhance candidate selection. Fourth, focusing on dual-use pipelines that span human and veterinary domains can maximize R&D ROI and open synergistic market channels. Fifth, actively engaging with regulatory authorities to co-create adaptive approval frameworks will ensure smoother pathways for emergency and full market authorizations. Finally, enhancing digital sales and patient engagement platforms, including telemedicine integrations, will streamline market uptake and support real-world evidence generation.

Conclusion: Seizing the DNA Vaccine Opportunity

DNA vaccines stand at a critical inflection point where scientific maturity converges with market opportunity. As delivery technologies improve and regulatory landscapes adapt, these platforms promise to transform immunization across infectious diseases, oncology, and beyond. The cumulative impact of evolving tariffs, shifting regional dynamics, and competitive corporate strategies underscores the need for agile planning and strategic partnerships. By leveraging insights from segmentation, geography, and industry players, stakeholders can navigate complexities and drive sustained innovation. The path forward demands both bold investments in novel technologies and thoughtful alignment with public health priorities. With coordinated efforts and data-driven decision making, DNA vaccines will realize their potential to deliver safer, more effective, and broadly accessible immunization solutions worldwide.

Market Segmentation & Coverage

This research report categorizes the DNA Vaccine Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Animal Vaccination
    • Companion Animal
    • Livestock
  • Human Vaccination
  • Prophylactic Vaccines
  • Therapeutic Vaccines
  • mRNA Platforms
  • Plasmid DNA Platforms
  • Viral Vector Platforms
  • Intradermal
  • Intramuscular
  • Mucosal Delivery
  • Allergies
  • Cancer
  • Infectious Diseases
    • Gastrointestinal Infections
    • Respiratory Infections
    • Sexually Transmitted Infections
  • Injectable
  • Nasal
  • Oral
  • Adult
  • Geriatric
  • Pediatric
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Emergency Use Authorization
  • Full Approval
  • In-House Manufacturing
  • Out-Sourced Manufacturing
  • Direct Sales
  • Online Pharmacy
  • Retail Pharmacy

This research report categorizes the DNA Vaccine Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the DNA Vaccine Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bioject Medical Technologies Inc.
  • Emergent BioSolutions
  • ExcellGene SA
  • Genentech, Inc.
  • GeneOne Life Science, Inc.
  • GeoVax Labs, Inc.
  • Immunomic Therapeutics, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • OncoSec Medical Incorporated
  • Profectus BioSciences, Inc.
  • TechnoVax Inc.
  • Vaccibody AS
  • Vaxess Technologies Inc.
  • Vical Incorporated

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. DNA Vaccine Market, by End-User Application
8.1. Introduction
8.2. Animal Vaccination
8.2.1. Companion Animal
8.2.2. Livestock
8.3. Human Vaccination
9. DNA Vaccine Market, by Product Type
9.1. Introduction
9.2. Prophylactic Vaccines
9.3. Therapeutic Vaccines
10. DNA Vaccine Market, by Technology Platform
10.1. Introduction
10.2. mRNA Platforms
10.3. Plasmid DNA Platforms
10.4. Viral Vector Platforms
11. DNA Vaccine Market, by Delivery Method
11.1. Introduction
11.2. Intradermal
11.3. Intramuscular
11.4. Mucosal Delivery
12. DNA Vaccine Market, by Disease Indication
12.1. Introduction
12.2. Allergies
12.3. Cancer
12.4. Infectious Diseases
12.4.1. Gastrointestinal Infections
12.4.2. Respiratory Infections
12.4.3. Sexually Transmitted Infections
13. DNA Vaccine Market, by Route of Administration
13.1. Introduction
13.2. Injectable
13.3. Nasal
13.4. Oral
14. DNA Vaccine Market, by Target Population
14.1. Introduction
14.2. Adult
14.3. Geriatric
14.4. Pediatric
15. DNA Vaccine Market, by Research and Development Phase
15.1. Introduction
15.2. Phase I
15.3. Phase II
15.4. Phase III
15.5. Preclinical
16. DNA Vaccine Market, by Approval Process
16.1. Introduction
16.2. Emergency Use Authorization
16.3. Full Approval
17. DNA Vaccine Market, by Business Model
17.1. Introduction
17.2. In-House Manufacturing
17.3. Out-Sourced Manufacturing
18. DNA Vaccine Market, by Sales Channel
18.1. Introduction
18.2. Direct Sales
18.3. Online Pharmacy
18.4. Retail Pharmacy
19. Americas DNA Vaccine Market
19.1. Introduction
19.2. Argentina
19.3. Brazil
19.4. Canada
19.5. Mexico
19.6. United States
20. Asia-Pacific DNA Vaccine Market
20.1. Introduction
20.2. Australia
20.3. China
20.4. India
20.5. Indonesia
20.6. Japan
20.7. Malaysia
20.8. Philippines
20.9. Singapore
20.10. South Korea
20.11. Taiwan
20.12. Thailand
20.13. Vietnam
21. Europe, Middle East & Africa DNA Vaccine Market
21.1. Introduction
21.2. Denmark
21.3. Egypt
21.4. Finland
21.5. France
21.6. Germany
21.7. Israel
21.8. Italy
21.9. Netherlands
21.10. Nigeria
21.11. Norway
21.12. Poland
21.13. Qatar
21.14. Russia
21.15. Saudi Arabia
21.16. South Africa
21.17. Spain
21.18. Sweden
21.19. Switzerland
21.20. Turkey
21.21. United Arab Emirates
21.22. United Kingdom
22. Competitive Landscape
22.1. Market Share Analysis, 2024
22.2. FPNV Positioning Matrix, 2024
22.3. Competitive Analysis
22.3.1. Amgen Inc.
22.3.2. Astellas Pharma Inc.
22.3.3. AstraZeneca plc
22.3.4. Bioject Medical Technologies Inc.
22.3.5. Emergent BioSolutions
22.3.6. ExcellGene SA
22.3.7. Genentech, Inc.
22.3.8. GeneOne Life Science, Inc.
22.3.9. GeoVax Labs, Inc.
22.3.10. Immunomic Therapeutics, Inc.
22.3.11. Inovio Pharmaceuticals, Inc.
22.3.12. Johnson & Johnson
22.3.13. Merck & Co., Inc.
22.3.14. Novartis AG
22.3.15. OncoSec Medical Incorporated
22.3.16. Profectus BioSciences, Inc.
22.3.17. TechnoVax Inc.
22.3.18. Vaccibody AS
22.3.19. Vaxess Technologies Inc.
22.3.20. Vical Incorporated
23. ResearchAI
24. ResearchStatistics
25. ResearchContacts
26. ResearchArticles
27. Appendix
List of Figures
FIGURE 1. DNA VACCINE MARKET MULTI-CURRENCY
FIGURE 2. DNA VACCINE MARKET MULTI-LANGUAGE
FIGURE 3. DNA VACCINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2024 VS 2030 (%)
FIGURE 26. GLOBAL DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 28. GLOBAL DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 32. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. DNA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 38. DNA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DNA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DNA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DNA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DNA VACCINE MARKET SIZE, BY COMPANION ANIMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DNA VACCINE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DNA VACCINE MARKET SIZE, BY HUMAN VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DNA VACCINE MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DNA VACCINE MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DNA VACCINE MARKET SIZE, BY MRNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DNA VACCINE MARKET SIZE, BY PLASMID DNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DNA VACCINE MARKET SIZE, BY VIRAL VECTOR PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DNA VACCINE MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DNA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DNA VACCINE MARKET SIZE, BY MUCOSAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DNA VACCINE MARKET SIZE, BY ALLERGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DNA VACCINE MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DNA VACCINE MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DNA VACCINE MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DNA VACCINE MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DNA VACCINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DNA VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DNA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DNA VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DNA VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DNA VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DNA VACCINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DNA VACCINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DNA VACCINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DNA VACCINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DNA VACCINE MARKET SIZE, BY EMERGENCY USE AUTHORIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DNA VACCINE MARKET SIZE, BY FULL APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DNA VACCINE MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DNA VACCINE MARKET SIZE, BY OUT-SOURCED MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DNA VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DNA VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DNA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. CANADA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. CANADA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. CANADA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 98. CANADA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 99. CANADA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 100. CANADA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 101. CANADA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. CANADA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 103. CANADA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 104. CANADA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 105. CANADA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 106. CANADA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. MEXICO DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. MEXICO DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 111. MEXICO DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 112. MEXICO DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 114. MEXICO DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. MEXICO DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 116. MEXICO DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 118. MEXICO DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES DNA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 161. CHINA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. CHINA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 163. CHINA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 164. CHINA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 165. CHINA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 166. CHINA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 167. CHINA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 168. CHINA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. CHINA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 170. CHINA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 171. CHINA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 172. CHINA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 173. CHINA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. INDIA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. INDIA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 176. INDIA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. INDIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 178. INDIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 179. INDIA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 180. INDIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 181. INDIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. INDIA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 183. INDIA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 184. INDIA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 185. INDIA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 186. INDIA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 191. INDONESIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 192. INDONESIA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 193. INDONESIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 194. INDONESIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. JAPAN DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. JAPAN DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 202. JAPAN DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. JAPAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 204. JAPAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 205. JAPAN DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 206. JAPAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 207. JAPAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. JAPAN DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 209. JAPAN DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 210. JAPAN DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 211. JAPAN DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 212. JAPAN DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 215. MALAYSIA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. MALAYSIA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. PHILIPPINES DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 228. PHILIPPINES DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. PHILIPPINES DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 230. PHILIPPINES DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 231. PHILIPPINES DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 232. PHILIPPINES DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 233. PHILIPPINES DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. SINGAPORE DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. SINGAPORE DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 241. SINGAPORE DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. SINGAPORE DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 243. SINGAPORE DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 244. SINGAPORE DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 245. SINGAPORE DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 246. SINGAPORE DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 249. SINGAPORE DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 251. SINGAPORE DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. SOUTH KOREA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 254. SOUTH KOREA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 256. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 257. SOUTH KOREA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 258. SOUTH KOREA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 259. SOUTH KOREA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. TAIWAN DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. TAIWAN DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 267. TAIWAN DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. TAIWAN DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 269. TAIWAN DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 270. TAIWAN DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 271. TAIWAN DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 272. TAIWAN DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. THAILAND DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. THAILAND DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 280. THAILAND DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 281. THAILAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 282. THAILAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 283. THAILAND DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 284. THAILAND DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 285. THAILAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. THAILAND DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 287. THAILAND DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 288. THAILAND DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 289. THAILAND DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 290. THAILAND DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. VIETNAM DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. VIETNAM DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 293. VIETNAM DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 294. VIETNAM DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 295. VIETNAM DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 296. VIETNAM DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 297. VIETNAM DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 298. VIETNAM DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 301. VIETNAM DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 302. VIETNAM DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 303. VIETNAM DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA DNA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 318. DENMARK DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 319. DENMARK DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 320. DENMARK DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 321. DENMARK DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 322. DENMARK DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 323. DENMARK DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 324. DENMARK DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 325. DENMARK DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. DENMARK DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 327. DENMARK DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 328. DENMARK DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 329. DENMARK DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 330. DENMARK DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. EGYPT DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 332. EGYPT DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 333. EGYPT DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 334. EGYPT DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 335. EGYPT DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 336. EGYPT DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 337. EGYPT DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 338. EGYPT DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 339. EGYPT DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 340. EGYPT DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 341. EGYPT DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 342. EGYPT DNA VACCINE MARKET SIZE, BY BUSINESS MODEL, 2018-2030 (USD MILLION)
TABLE 343. EGYPT DNA VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
TABLE 344. FINLAND DNA VACCINE MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 345. FINLAND DNA VACCINE MARKET SIZE, BY ANIMAL VACCINATION, 2018-2030 (USD MILLION)
TABLE 346. FINLAND DNA VACCINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 347. FINLAND DNA VACCINE MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 348. FINLAND DNA VACCINE MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 349. FINLAND DNA VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 350. FINLAND DNA VACCINE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 351. FINLAND DNA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 352. FINLAND DNA VACCINE MARKET SIZE, BY TARGET POPULATION, 2018-2030 (USD MILLION)
TABLE 353. FINLAND DNA VACCINE MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 354. FINLAND DNA VACCINE MARKET SIZE, BY APPROVAL PROCESS, 2018-2030 (USD MILLION)
TABLE 355. FINLAND DNA VACCINE MARKET SIZE, BY BUSI

Companies Mentioned

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bioject Medical Technologies Inc.
  • Emergent BioSolutions
  • ExcellGene SA
  • Genentech, Inc.
  • GeneOne Life Science, Inc.
  • GeoVax Labs, Inc.
  • Immunomic Therapeutics, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • OncoSec Medical Incorporated
  • Profectus BioSciences, Inc.
  • TechnoVax Inc.
  • Vaccibody AS
  • Vaxess Technologies Inc.
  • Vical Incorporated

Methodology

Loading
LOADING...

Related Topics

Related Reports

DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030 - Product Image

DNA Vaccine Market by Type, Application, End-User, Delivery Method, Technology, Therapeutic Area, Route of Administration - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Aquaculture Vaccines Market by Type, Product, Route of Administration, Application, End-User - Global Forecast 2025-2030 - Product Image

Aquaculture Vaccines Market by Type, Product, Route of Administration, Application, End-User - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Vaccine Contract Manufacturing - Global Strategic Business Report - Product Image

Vaccine Contract Manufacturing - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Global Porcine Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Porcine Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Porcine Vaccines - Global Strategic Business Report - Product Image

Porcine Vaccines - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.